TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Status:
RECRUITING
Trial end date:
2029-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this single- arm, open-label, dose escalation and dose expansion phase I/II study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-814 in patients with hematological malignancies including non-Hodgkin lymphoma, acute myeloid leukemia, aute lymphoblastic leukemia and myelodysplastic syndromes.
Phase:
PHASE1
Details
Lead Sponsor:
Shenzhen TargetRx, Inc.
Collaborator:
Institute of Hematology & Blood Diseases Hospital, China